Lv3
240 积分 2022-11-21 加入
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
2天前
已完结
Discovery and development of SIM0709, a novel bi-specific antibody targeting TL1A and IL23p19 for the treatment of IBD and beyond 4676
2个月前
已完结
P0011 Functional Advantage of Afimkibart’s Preference for Trimeric TL1A in Blocking Active TL1A Signaling
2个月前
已关闭
Novel Small-Molecule miR-124 Inducer Acts as “a Physiological Brake” of Inflammation in Ulcerative Colitis by Targeting the PIK3R2/PI3K/Akt Axis
3个月前
已完结
Differentiation and Polarization of THP-1 Cells into M1 and M2 Macrophages for Cancer Research
4个月前
已完结
Targeting focal adhesion kinase (FAK) in non-small cell lung cancer (NSCLC): Molecular mechanisms and combination therapeutic strategies
5个月前
已完结
MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells
5个月前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
5个月前
已完结
Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer
5个月前
已完结
MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells
5个月前
已完结
皖公网安备34019202002308
